A carregar...
HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss
HER2-positive breast cancer (HER2+ BC) is an aggressive subtype with a poor prognosis. Although the antibody trastuzumab, which targets the HER2 growth factor receptor, has improved survival rates, patients often present with de novo resistance or acquire resistance after an initial response. Identi...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5413028/ https://ncbi.nlm.nih.gov/pubmed/28463969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0176778 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|